长春瑞滨
转移性乳腺癌
医学
肿瘤科
内科学
HER2阴性
倾向得分匹配
噻替帕
乳腺癌
癌症
化疗
顺铂
环磷酰胺
作者
Aurélien Robert,Paul Gougis,Élise Dumas,Rebecca Loison,Victoire de Castelbajac,Marc Espié,Sylvie Giacchetti,C. Cuvier,L. Hassani,Johanna Wassermann,Luca Campedel,Marianne Veyri,Aurore Vozy,Jean Philippe Spano,Luís Teixeira,Baptiste Abbar
摘要
ABSTRACT Background Vinorelbine is commonly used to treat metastatic breast cancer (mBC), while thiotepa is known for its ability to cross the blood–brain barrier. Methods Our retrospective study aimed to compare the efficacy and safety of vinorelbine with or without thiotepa in patients with HER2‐negative mBC. We used propensity score inverse probability of treatment weighting to ensure comparability between groups. Results Vinorelbine‐thiotepa was not significantly associated with improved median progression‐free survival (PFS) (4.9 vs. 3.0 months, p = 0.138) or median overall survival (OS) (11.8 vs. 11.9 months, p = 0.961) compared to vinorelbine. However, in the central nervous system (CNS) metastasis subgroup, vinorelbine‐thiotepa was associated with a longer median PFS (4.9 vs. 2.1 months, p = 0.013) and CNS‐PFS (6.12 vs. 2.20 months, p = 0.007). The combination was also associated with a higher rate of grade ≥ 3 adverse events (54.3% vs. 37.9%, p = 0.021). Conclusion While no overall benefit in PFS or OS was found, vinorelbine‐thiotepa may be associated with improved PFS in mBC patients with CNS metastasis.
科研通智能强力驱动
Strongly Powered by AbleSci AI